← Back to headlines
Immunic Closes $200M Private Placement for MS Trials
Immunic has closed a $200 million private placement to fund late-stage multiple sclerosis trials, securing significant capital for its research and development.
17 Feb, 21:33 — 17 Feb, 21:33
ℹOnly 1 source covers this story
